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Background: Mupirocin is widely used for nasal decolonization of Staphylococcus aureus to prevent subsequent
staphylococcal infection in patients and healthcare personnel. However, the prolonged and unrestricted use has
led to the emergence of mupirocin-resistant (mupR) S. aureus. The aim of this systematic review was to investigate
the prevalence, phenotypic and molecular characteristics, and geographic spread of mupR S. aureus in Africa.
Methods: We examined five electronic databases (EBSCOhost, Google Scholar, ISI Web of Science, MEDLINE, and
Scopus) for relevant English articles on screening for mupR S. aureus from various samples in Africa. In addition, we
performed random effects meta-analysis of proportions to determine the pooled prevalence of mupR S. aureus in
Africa. The search was conducted until 3 August 2016.
Results: We identified 43 eligible studies of which 11 (26%) were obtained only through Google Scholar. Most of
the eligible studies (28/43; 65%) were conducted in Nigeria (10/43; 23%), Egypt (7/43; 16%), South Africa (6/43; 14%)
and Tunisia (5/43; 12%). Overall, screening for mupR S. aureus was described in only 12 of 54 (22%) African
countries. The disk diffusion method was the widely used technique (67%; 29/43) for the detection of mupR S.
aureus in Africa. The mupA-positive S. aureus isolates were identified in five studies conducted in Egypt (n = 2),
South Africa (n = 2), and Nigeria (n = 1). Low-level resistance (LmupR) and high-level resistance (HmupR) were both
reported in six human studies from South Africa (n = 3), Egypt (n = 2) and Libya (n = 1). Data on mupR-MRSA was
available in 11 studies from five countries, including Egypt, Ghana, Libya, Nigeria and South Africa. The pooled
prevalence (based on 11 human studies) of mupR S. aureus in Africa was 14% (95% CI =6.8 to 23.2%). The
proportion of mupA-positive S. aureus in Africa ranged between 0.5 and 8%. Furthermore, the frequency of S.
aureus isolates that exhibited LmupR, HmupR and mupR-MRSA in Africa were 4 and 47%, 0.5 and 38%, 5 and 50%,
respectively.
Conclusions: The prevalence of mupR S. aureus in Africa (14%) is worrisome and there is a need for data on
administration and use of mupirocin. The disk diffusion method which is widely utilized in Africa could be an
important method for the screening and identification of mupR S. aureus. Moreover, we advocate for surveillance
studies with appropriate guidelines for screening mupR S. aureus in Africa.
Keywords: Africa, Prevalence, Meta-analysis, Mupirocin, Staphylococcus aureus, Systematic review* Correspondence: bayo_shittu@yahoo.com
1Department of Microbiology, Obafemi Awolowo University, Ile-Ife, Osun
State 22005, Nigeria
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Shittu et al. Antimicrobial Resistance and Infection Control  (2018) 7:101 Page 2 of 16Background
Staphylococcus aureus is a well-recognized human patho-
gen that is implicated in a wide array of superficial,
invasive and toxigenic infections [1]. Meta-analyses of
published studies have provided evidence that S. aureus
nasal carriage is an important risk factor for subsequent
infection among patients with surgical site infections and
atopic dermatitis [2, 3]. Other high-risk groups include pa-
tients colonized with methicillin-resistant Staphylococcus
aureus (MRSA) undergoing dialysis, and patients admitted
in the intensive care unit [4, 5]. Consequently, infection
prevention strategies such as nasal decolonization are
employed to minimize the occurrence of staphylococcal
infection and reduce the risk of transmission in healthcare
settings [6, 7]. Mupirocin (2%) nasal ointment alone or in
combination with 4% chlorhexidine (CHG) based body
wash is considered as the main decolonization strategy for
S. aureus carriage [8, 9]. Mupirocin is a naturally occur-
ring antibiotic produced by Pseudomonas fluorescens that
interferes with protein synthesis by competitive inhibition
of the bacterial isoleucyl-tRNA synthetase (IRS) [10, 11].
It gained prominence in the mid-1990s for the eradication
of S. aureus nasal carriage due to its effectiveness, safety
and cost [12].
Mupirocin-resistant (mupR) S. aureus was first reported
in the United Kingdom in 1987 [13]. Since then, it has been
reported in several countries worldwide [14–17]. The emer-
gence of mupR S. aureus has been associated with unre-
stricted policies and use of mupirocin for long periods in
health care settings [8, 18]. Decolonization failure in pa-
tients with S. aureus carriage is associated with high-level
mupirocin resistance (HmupR - minimum inhibitory con-
centration [MIC]: ≥512 μg/ml), while that of low-level
mupirocin resistance (LmupR – MIC: 8-64 μg/ml) is still
unclear [7, 19]. LmupR is mediated through point mutation
(largely V588F and V631F) in the native isoleucyl-tRNA
synthetase (ileS) gene [20]. In contrast, HmupR is mainly
attributed to the acquisition of plasmids with the mupA (or
ileS2) gene encoding an additional IRS with no affinity for
mupirocin [11, 21]. Another determinant for HmupR is the
acquisition of a plasmid-mediated mupB gene [22].
There is no data summarizing reports on screening,
prevalence, characterization, and geographic spread of
mupR S. aureus in Africa. This systematic review evaluated
published articles that assessed for mupirocin resistance in
African S. aureus isolates. The findings from this systematic
review highlight the need to develop an early warning sys-
tem, including harmonized strategies for the prompt
screening and identification of mupR S. aureus in Africa.
Methods
Literature search strategy
The relevant English articles from human and animal in-
vestigations were retrieved by three authors (YA, SA,and AS) from five electronic databases (EBSCOhost,
Google Scholar, ISI Web of Science, MEDLINE, and
Scopus). The search terms for each database are re-
ported in Table 1. The literature search was concluded
on 3 August 2016.
Eligible article identification
The identification of the eligible articles was conducted
according to the guidelines for preferred reporting items
for systematic reviews and meta-analyses (PRISMA)
[23]. We defined an eligible article as a peer-reviewed
publication that (i) included mupirocin in the antibiotic
susceptibility testing of S. aureus isolates, and (ii)
employed phenotypic ((disc diffusion, E-test, minimum
inhibitory concentration (MIC), VITEK and other auto-
mated methods)), and/or molecular ((conventional or
real-time polymerase chain reaction (PCR)) techniques.
International multicentre studies that included African
countries were also eligible for inclusion.
Data extraction and analysis
The relevant data were extracted from each of the eligible
articles included in this systematic review. A study that
analysed S. aureus isolates from another investigation but
answered a different research question were both consid-
ered as one study (Table 2). We performed three levels of
analysis (Fig. 1). First, to understand the characteristics
and geographic spread of mupR S. aureus in Africa,
studies that included mupirocin in the antibiotic suscepti-
bility testing and employed phenotypic and/or molecular
techniques were identified. Secondly, the prevalence of
S. aureus with the mupA gene, isolates that expressed
LmupR and HmupR, and mupR-MRSA in Africa were
derived from each eligible study as follows:
MupA‐positive S: aureus
¼ Number of MupA‐positive S: aureus isolates
Total number of isolates screened with mupirocin
S: aureus that expressed LmupR
¼ Number of S: aureus isolates with LmupR
Total number of isolates screened with mupirocin
S: aureus that expressed HmupR
¼ Number of S: aureus isolates with HmupR
Total number of isolates screened with mupirocin
MupR‐MRSA
¼ Number of mupR‐MRSA isolates
Total number of isolates screened with mupirocin
Thirdly, to estimate the prevalence of mupR S. aureus in
humans, studies that employed at least one of the screen-
ing methods with defined breakpoint for mupirocin resist-
ance were included in the meta-analysis. The StatsDirect
Table 1 Keywords used to identify eligible studies available in five biomedical databases
Database Search period Search strategy
MEDLINE via PubMed
EBSCOhost via Academic Search premier,
Africa-Wide information and CINAHL
1974 - August 2016
1982 - August 2016




(Algeria OR Angola OR Benin OR Botswana OR Burkina Faso OR “Burkina Faso”
OR Burkina Fasso OR Upper Volta OR “Upper Volta” OR Burundi OR Cameroon
OR Cape Verde OR “Cape Verde” OR Central African Republic OR Chad OR
Comoros OR “Iles Comores” OR Iles Comores OR Comoro Islands OR “Comoro
Islands” OR Congo OR Democratic Republic Congo OR “Democratic Republic
of the Congo” OR Zaire OR Djibouti OR Egypt OR Equatorial Guinea OR
“Equatorial Guinea” OR Eritrea OR Ethiopia OR Gabon OR Gambia OR Ghana
OR Guinea OR Guinea Bissau OR “Guinea Bissau” OR Ivory Coast OR “Ivory
Coast” OR Cote d’Ivoire OR “Cote d’Ivoire” OR Kenya OR Lesotho OR Liberia
OR Libya OR Libia OR Jamahiriya OR Jamahiryia OR Madagascar OR Malawi
OR Mali OR Mauritania OR Mauritius OR Ile Maurice OR “Ile Maurice” OR
Morocco OR Mozambique OR Moçambique OR Namibia OR Niger OR Nigeria
OR Rwanda OR Sao Tome OR “Sao Tome” OR Senegal OR Seychelles OR
Sierra Leone OR “Sierra Leone” OR Somalia OR South Africa OR “South Africa”
OR Sudan OR South Sudan OR “South Sudan” OR Swaziland OR Tanzania OR
Tanganyika OR Zanzibar OR Togo OR Tunisia OR Uganda OR Western Sahara
OR “Western Sahara” OR Zambia OR Zimbabwe OR Africa OR Africa* OR
Southern Africa OR West Africa OR Western Africa OR Eastern Africa OR East
Africa OR North Africa OR Northern Africa OR Central Africa OR Sub Saharan
Africa OR Subsaharan Africa OR Sub-Saharan Africa)
NOT
(Guinea pig* OR “Guinea pig*” OR Aspergillus niger OR “Aspergillus niger”
OR Europe* OR America* OR Asia*)
ISI Web of Science 1950 - August 2016









(Name of each African country)
Examples
(Staphylococcus aureus OR S. aureus) AND (Mupirocin) AND (Algeria)
(Staphylococcus aureus OR S. aureus) AND (Mupirocin) AND (Zimbabwe)
aThe African countries were manually selected (as recommended by Scopus database) to exclude studies from other continents
**The Google Scholar search was conducted between July-September 2015
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ectLtd.2016) was utilized to assess the heterogeneity of
the eligible studies included in the meta-analysis
(Cochran Q-test) [24], and to ascertain the inconsist-
ency across the studies (I2 statistic) [25]. The random
effects model was used to determine the pooled preva-
lence of mupR S. aureus in Africa. The criterion for
statistical significance for heterogeneity was set at
alpha = 0.05. The risk of publication bias was assessed
and visualized by a Funnel plot [26, 27].Results
Eligible studies from electronic database search
We identified 43 reports (Table 1) of which 34 studies
investigated only human samples. The remaining nine
studies assessed samples from only animals (n = 5),
human and environmental sources (n = 2), human andanimal sources (n = 1), and cockroaches (n = 1). Most
of the eligible studies (32/43; 74%) were obtained from
EBSCOhost, ISI Web of Science, MEDLINE, and Scopus.
The remaining studies (11/43; 26%) were obtained
only through Google Scholar and consisted of studies
conducted in Egypt [28–31], South Africa [32–34],
Nigeria [35, 36], Ethiopia [37] and Kenya [38].
Screening and identification of mupR S. aureus in Africa
Only 12 of the 54 (22%) African countries reported data
on screening for mupR S. aureus (Fig. 2). The first pub-
lished article indicated that mupirocin had been in use in
Africa, at least from the late 1980s [39]. Most of these
studies (28/43; 65%) were conducted in Nigeria (10/43;
23%), Egypt (7/43; 16%), South Africa (6/43; 14%) and
Tunisia (5/43; 12%) (Fig. 2). MupR S. aureus was mainly
identified through the disk diffusion method (29/43; 67%).
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3177 articles identified through Google scholar90 articles identified through database search:
• 33 in PubMed;
• 39 in EBSCOhost;
• 14 in Web of Science;
• 4 in Scopus
3168 articles after duplicates removed
3168 articles screened 3120 articles excluded based on title and abstracts
48 Full-text articles assessed for eligibility
3 Full-text articles excluded, with reasons:
• 1 article was not written in English
• 1 study involved pilgrims from different 
countries though carried out in Africa
• 1 study made use of X-ray
45 articles included in systematic review
43 articles included in analysis of systematic review
11 articles included in meta-analysis
2 separate articles that analyzed the same S. aureus
isolate but answered different questions
Fig. 1 The Preferred Reporting Items for Systematic Review and Meta-analysis flow diagram
Shittu et al. Antimicrobial Resistance and Infection Control  (2018) 7:101 Page 8 of 16Institute (CLSI), previously known as National Committee
for Clinical Laboratory Standards (NCCLS), were broadly
used in Africa (Table 2). However, a number of studies
[28, 29, 31, 33, 36, 40–46] utilized the disk diffusion
method with CLSI guidelines that had no zone diam-
eter breakpoint for mupirocin. Moreover, some studies
[47–49] did not provide information on the year of
























Fig. 2 Studies on screening for mupirocin-resistant Staphylococcus aureus ireported in six African countries including South Africa
[32–34, 46, 50, 51], Egypt [29–31, 52], Nigeria [36, 44,
53], Ghana [54, 55], Libya [56, 57] and Ethiopia [37]
(Fig. 2; Table 2). The mupA-positive S. aureus was de-
tected in five studies from Egypt [30, 52], South Africa
[33, 50] and Nigeria [53]. LmupR and HmupR were
both reported in six human studies conducted in South
Africa [32, 33, 50], Egypt [30, 52] and Libya [57]. The3
1 1 1 1 1
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34, 50, 51], Egypt [30, 31, 52], Libya [56, 57], Ghana [55]
and Nigeria [36] (Table 3). MupR-MRSA was not reported
from MRSA isolates recovered from studies conducted in
Egypt [28, 58], Tunisia [59, 60] and Algeria [47].
An assessment of data on mupR S. aureus at the re-
gional level is described as follows (Fig. 3).North Africa
Seventeen eligible studies were recorded from this region,
including Egypt [28–31, 40, 52, 58], Tunisia [41–43, 59,
60], Libya [56, 57, 61], Algeria [47] and Morocco [62].
MupR S. aureus was reported in six studies conducted in
two North African countries: Egypt [29–31, 52] and Libya
[56, 57]. PCR detection of the mupA gene was performed
in only two studies conducted in Egypt [30, 52]. In
addition, one of the reports identified two mupA positive
MRSA that exhibited LmupR [30]. MupR S. aureus was
not detected in Tunisia [41–43, 59, 60], Algeria [47], and
Morocco [62].Fig. 3 Geographic distribution of mupirocin-resistant (mupR) Staphylococcu
been investigated but not reported. Countries (in red) in which mupR S. auWest Africa
S. aureus resistance to mupirocin was investigated in
Nigeria [35, 36, 44, 48, 49, 53, 63–66] and Ghana [54, 55,
67, 68]. Only two studies from Ghana reported on mupR
S. aureus [54, 55]. In Nigeria, three studies (including two
from only human sources and one from both animal and
human samples, respectively) reported on S. aureus iso-
lates that demonstrated HmupR [36, 44, 53].
Central Africa
MupR S. aureus was not detected in studies conducted
in Gabon [69], and São Tomé and Príncipe [70].
East Africa
In this review, we identified four eligible studies con-
ducted in Kenya [38, 71, 72] and Ethiopia [37]. A report
on the role of cockroaches as potential vectors of food-
borne pathogens in Ethiopia identified 17 mupR S. aur-
eus isolates [37]. All the S. aureus isolates (one animal
and two human studies) from Kenya were susceptible to
mupirocin [38, 71, 72].s aureus in Africa. Countries (in green) in which mupR S. aureus have
reus have been investigated and reported
Shittu et al. Antimicrobial Resistance and Infection Control  (2018) 7:101 Page 12 of 16Southern Africa
The six studies reported in this geographical area were
from South Africa and consisted of two single centre
studies [34, 46] and four multicenter studies [32, 33, 50,
51]. MupR S. aureus was identified in all the reports,
while mupA-positive S. aureus isolates were noted in
only two studies [33, 50].
Prevalence of mupR S. aureus in Africa
The random-effects pooled prevalence of mupR S. aureus
in Africa is 14% (95% CI =6.8 to 23.2%). This was calcu-
lated based on 11 heterogeneous human studies (Figs. 4
and 5) conducted in South Africa [32, 33, 50, 51], Ghana
[54, 55], Egypt [30, 52], Libya [56, 57] and Nigeria [53]. In
Africa, the proportion of S. aureus isolates with the
mupA gene, and those that expressed LmupR and
HmupR ranged between 0.5 and 8%, 4 and 47%, 0.5
and 38%, respectively. The frequency of mupR-MRSA
isolates ranged between 5 and 50% (Table 3).
Association of MupR S. aureus with mupirocin use in
Africa
There is no data on the use of mupirocin as an agent for
S. aureus decolonization and its association with mupR
S. aureus in Africa.
MupR S. aureus and biofilm production
A report from Egypt noted that mupR-MRSA were mod-
erate to strong biofilm producers [52].Fig. 4 Bias assessment (Funnel) plot for studies assessing rates of mupiroci
(DerSimonian-Laird). Pooled proportion = 0.139303 (95% CI = 0.067511 to 0
Egger: bias = 4.771137 (95% CI = −2.517874 to 12.060148) P = 0.1728, HarboMupR S. aureus and co-resistance to other antibiotics
In this systematic review, two studies (conducted in Egypt
and South Africa) showed that mupR S. aureus was asso-
ciated with multi-drug resistance [30, 33].
Molecular characterization of mupR S. aureus in Africa
Only three studies provided molecular data on mupR S.
aureus in Africa [45, 54, 55]. A report provided evidence
of a 35 kb (non-conjugative) and 41.1 kb (conjugative)
plasmid encoding mupA in S. aureus isolates from Nigeria
and South Africa [45]. It also described an MRSA clone
that demonstrated LmupR in South Africa. LmupR was
also identified among MRSA isolates assigned with ST36,
ST88, and ST789 in Ghana [55]. A cross-sectional S. aur-
eus study identified a methicillin susceptible S. aureus
(MSSA) strain with HmupR from a 51-year-old hospital
staff in Ghana [54]. Molecular characterization indicated
that the strain (spa type t4805) was PVL-positive.
Discussion
This is the first systematic review on mupR S. aureus in
Africa and clearly showed the paucity of data on the
continent. Nevertheless, this study indicated a high
prevalence ((14% (95% CI =6.8 to 23.2)) of mupR S. aur-
eus in Africa. These observations support the need for
mupR S. aureus surveillance data to provide information
on its epidemiology and clinical significance in Africa. It
is noteworthy that Google Scholar was valuable in the
identification of several eligible studies [28–38]. Wen-resistant Staphylococcus aureus in Africa. Random effects
.23165). Bias indicators, Begg-Mazumdar: Kendall’s tau = 0.2 P = 0.4454,
rd: bias = 2.014783 (92.5% CI = −5.90181 to 9.931377) P = 0.6208
Fig. 5 Pooled estimate of proportions (human studies) for mupirocin-resistant Staphylococcus aureus in Africa
Shittu et al. Antimicrobial Resistance and Infection Control  (2018) 7:101 Page 13 of 16observed that 26% (11/43) of the eligible studies were
identified from African journals which were not indexed
in commonly used electronic databases. Google Scholar
has been considered as a useful supplement with other
electronic databases for systematic review search [73] in-
cluding recent meta-analyses of published studies on S.
aureus in Africa [74, 75].
The phenotypic methods for the screening and iden-
tification of mupR S. aureus include disc diffusion
(two-disc strategy: 5 μg and 200 μg), agar dilution,
broth micro-dilution and E-test [19]. In this study, the
disk diffusion method and the CLSI (formerly NCCLS)
guidelines were strategies mainly applied to detect mupR
S. aureus in Africa. However, we observed certain incon-
sistencies [28, 29, 31, 33, 36, 40–49]. For instance, a num-
ber of studies [28, 29, 31, 33, 36, 40–42, 44–46] applied
the disk diffusion method with the CLSI guidelines that
had no breakpoint values for mupirocin. The 2017 CLSI
guidelines recommend the use of the 200 μg disk to differ-
entiate between HmupR and the absence of HmupR (i.e.
no zone =HmupR; any zone = absence of HmupR) [76].
The 200 μg disk with a different breakpoint (Susceptible
≥30 mm, Resistance < 18 mm) is also endorsed for the dif-
ferentiation between HmupR and the absence of HmupR
in the latest versions (accessed 28th May, 2018) of the
European Committee for Antimicrobial Susceptibility
Testing (EUCAST) and Comité de l’antibiogramme de laSociété Française de Microbiologie (CA-SFM) [77, 78].
The breakpoint values for the detection of LmupR and
differentiation from HmupR are not provided in these
documents (CA-SFM, CLSI, and EUCAST). Despite
this limitation, the disk diffusion method in conjunc-
tion with any of these guidelines could at least be valu-
able for the preliminary screening and identification of
HmupR S. aureus in Africa. MRSA decolonization failure
is of clinical significance as it is often attributed to persist-
ence or re-colonization associated with isolates exhibiting
HmupR, while that of LmupR is not clear [7, 19, 79]. In
this review, the prevalence of S. aureus that exhibited
LmupR, HmupR and mupR-MRSA in Africa was predi-
cated on a range of methods using different guidelines.
We suggest that surveillance data from Africa is estab-
lished on harmonized guidelines to enhance quality assur-
ance and comparison at the continental and global level.
We noted a prevalence of mupR-MRSA ranging
between 5 and 50% in Africa (Table 3). This is of serious
concern. Specifically, the relationship between mupiro-
cin resistance and MRSA has important consequences
on infection control measures and effectiveness of
decolonization strategies [8]. MupR-MRSA could limit
the choices available for the control and prevention of
healthcare-associated MRSA infections (7, 8). There-
fore, surveillance studies are important to investigate
the emergence and spread of mupirocin resistance in
Shittu et al. Antimicrobial Resistance and Infection Control  (2018) 7:101 Page 14 of 16hospital settings in Africa. This is important among pa-
tients at high risk of MRSA infections, including patients
in the dermatology, dialysis and the Intensive Care Units.
In addition, there is the need for more data on the mo-
lecular characterization of mupR S. aureus in Africa [45,
54, 55]. For instance, whole genome sequencing (WGS)
will assist in understanding the transmission dynamics of
mupR S. aureus in Africa. Moreover, WGS data will allow
comprehensive investigation of the genetic basis for
LmupR mutation (which is largely due to V588F and
V631F in the native gene (ileS)) and mupB-positive S. aur-
eus in Africa.
Language bias was the main limitation of this system-
atic review as we did not include studies published in
French, Portuguese, Arabic and Spanish.
Conclusions
This study showed the need for more epidemiological data
to understand the transmission, burden and risk factors
associated with mupR S. aureus in Africa. In addition,
there is a need for data on administration and use of
mupirocin in community and hospital setting in Africa.
This is important in antibiotic stewardship to mitigate the
emergence and spread of mupR S. aureus in Africa.
Finally, this systematic review highlighted the need for
harmonized guidelines to facilitate the comparison of data
on mupR S. aureus from Africa.
Abbreviation
HmupR: High-level mupirocin resistance; LmupR: Low-level mupirocin
resistance; MIC: Minimum inhibitory concentration; MRSA: Methicillin-resistant
Staphylococcus aureus; MSSA: Methicillin-susceptible S. aureus;
mupR: Mupirocin-resistant; PCR: Polymerase chain reaction; PVL: Panton
Valentine Leucocidin; S. aureus: Staphylococcus aureus; ST: Sequence type
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